BCR-ABL kinase domain mutations and clonal evolution as major causes of resistance to targeted therapy in chronic myelogenous leukemia

被引：0
|
作者：
Andrikovics, H.
Meggyesi, N.
Lueff, S.
Batai, A.
Adam, E.
Kozma, A.
Halm, G.
Nahajevszky, S.
Kapas, B.
Csukly, Z.
Lovas, N.
Remenyi, P.
Tordai, A.
Masszi, T.
机构：
[1] Natl Med Ctr, Dept Mol Diagnost, Budapest, Hungary
[2] Natl Med Ctr, Dept Hematol & Stem Transplantat, Budapest, Hungary
来源：
BLOOD REVIEWS | 2007年 / 21卷
关键词：
D O I：
10.1016/S0268-960X(07)70054-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S78 / S79
页数：2
相关论文
共 50 条
  • [41] BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells
    Brauer, Katharina M.
    Werth, Daniela
    von Schwarzenberg, Karin
    Bringmann, Anita
    Kanz, Lothar
    Gruenebach, Frank
    Brossart, Peter
    CANCER RESEARCH, 2007, 67 (11) : 5489 - 5497
  • [42] Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
    Elias, Marjanu Hikmah
    Baba, Abdul Aziz
    Husin, Azlan
    Abdullah, Abu Dzarr
    Hassan, Rosline
    Sim, Goh Ai
    Wahid, S. Fadilah Abdul
    Ankathil, Ravindran
    HEMATOLOGY REPORTS, 2012, 4 (04) : 86 - 90
  • [43] BCR-ABL - AN ANTI-APOPTOSIS GENE IN CHRONIC MYELOGENOUS LEUKEMIA
    COTTER, TG
    LEUKEMIA & LYMPHOMA, 1995, 18 (3-4) : 231 - 236
  • [44] RAS IS ESSENTIAL FOR TRANSFORMATION BY THE BCR-ABL ONCOGENE OF CHRONIC MYELOGENOUS LEUKEMIA
    SAWYERS, CL
    MCLAUGHLIN, J
    HAVLIK, M
    WITTE, O
    BLOOD, 1993, 82 (10) : A331 - A331
  • [45] Mechanism of stability and degradation of the chronic myelogenous leukemia oncoprotein, BCR-ABL
    Tsukahara, F
    Maru, Y
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 105P - 105P
  • [46] Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more
    Cea, M.
    Cagnetta, A.
    Garuti, A.
    Cirmena, G.
    Rocco, I.
    Moran, E.
    Grillo, V.
    Ballestrero, A.
    Patrone, F.
    Nencioni, A.
    JOURNAL OF BUON, 2009, 14 (04): : 565 - 573
  • [47] BCR-ABL kinase domain mutations in patient with secondary but not primary resistance to imatinib.
    Al-Ali, HK
    Lange, T
    Krahl, R
    Mueller, C
    Patzer, G
    Niederwieser, D
    Deininger, MWN
    BLOOD, 2002, 100 (11) : 368A - 369A
  • [48] ALTERNATIVE 5' END OF THE BCR-ABL TRANSCRIPT IN CHRONIC MYELOGENOUS LEUKEMIA
    ROMERO, P
    BERAN, M
    SHTALRID, M
    ANDERSSON, B
    TALPAZ, M
    BLICK, M
    ONCOGENE, 1989, 4 (01) : 93 - 98
  • [49] Additional Chromosome Abnormalities, BCR-ABL Tyrosine Kinase Domain Mutations and Clinical Outcome in Hungarian Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia Patients
    Meggyesi, Nora
    Kozma, Andras
    Halm, Gabriella
    Nahajevszky, Sarolta
    Batai, Arpad
    Fekete, Sandor
    Barta, Aniko
    Ujj, Gyoergy
    Lueff, Sandor
    Sipos, Andrea
    Adam, Emma
    Bors, Andras
    Remenyi, Peter
    Masszi, Tamas
    Tordai, Attila
    Andrikovics, Hajnalka
    ACTA HAEMATOLOGICA, 2012, 127 (01) : 34 - 42
  • [50] Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
    Cortes, Jorge
    Jabbour, Elias
    Kantarjian, Hagop
    Yin, C. Cameron
    Shan, Jianqin
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Giles, Francis
    Breeden, Megan
    Reeves, Nubia
    Wierda, William G.
    Jones, Dan
    BLOOD, 2007, 110 (12) : 4005 - 4011
12345